Dear Sir,

We would like to bring to your attention a Special situation opportunity on the demerger of two businesses in PTL Enterprises.

We initiated this opportunity for our Alpha + members in Aug’16 around 119 odd levels and recently closed the same around 150.

Besides investing in high quality small/mid cap companies for long term wealth creation, we also like to participate in slightly shorter duration Special situation opportunities arising out of corporate actions like de-merger, de-listing, buy-back, etc

With de-mergers we have had good experience over the years and would therefore like to share the detailed note on PTL Enterprises de-merger opportunity with you.


4 New Reports: 2 new long term investment report and 2 Special Situation opportunities:

  1. Feb’17 – High probability of 100% acceptance of shares
  2. Jan’17 – High quality debt free company consistently growing at 18-20%
  3. Jan’17 – An opportunity to create low cost shares
  4. Nov’16 – Transforming from commodity to a brand

Register yourself HERE On subscribing to Alpha + you will get access to all the above latest Reports.


PTL Enterprises (NSE Code – PTL)

(Alpha + Note as on 7th Aug’16)

PTL enterprises is an associate company of Apollo Tyres Ltd. PTL Enterprises, earlier know as Premier Tyres Limited, was set up in 1959 as a tyre manufacturing company. The company became a “sick unit,” following a series of losses, liquidity pressures, and labour issues during the early 1990s. Apollo Tyres took over the company in 1995.

The company has two divergent businesses. It has a tyre manufacturing facility located at Kerala, which has been leased out to its associate company Apollo Tyres Limited (“Tyre Business”). PTL is also engaged in the business of providing and promoting medicare and healthcare services through Artemis Health Institute, Gurgaon (the “Medicare and Healthcare Services Business”).

Proposed De-merger and the scheme of arrangement

The businesses in which PTL is engaged are varied in nature and in order to facilitate the growth and development of each of the businesses the management has proposed to demerge the Medicare and Healthcare Undertaking from PTL into the Resulting Company AGLSL.

As per the proposed scheme of de-merger, the healthcare business will be demerged from PTL into AGLSL and it will subsequently list on the exchanges as a separate entity.

In consideration of the demerger of healthcare business, the existing shareholders of PTL will get 1 new share of AGLSL for every 1 share held in PTL as on record date.

Tyre business

PTL owns a land parcel of around 31 acres in Kochi and has a tyre manufacturing facility on the same which it has leased out to Apollo Tyres.

The salient terms of the lease agreement are as below:

The current lease agreement is valid up to 31st Mar 2022.

Earlier the lease rent was Rs 40 crores per annum; however the same has now been revised to Rs 50 crores per annum

For FY 16, on standalone basis the tyre business recorded PBT of Rs 37.61 crores. On standalone basis the company is debt free so we don’t expect any interest cost in FY 17. Further, in FY 17 the company will get full year benefit of revision in lease rent to 50 crore and therefore expect the company to record PBT of ~43-44 crores.

On the basis of earnings, we expect tyre business (similar to bond coupon) to trade at ~ 8-12 times PBT and expect the business to trade at market capitalization of ~350-500 crores.

Recently, an independent firm has assessed the value of land parcel of the company at 568 crores.

Further, some time back Govt. of Kerala acquired 1.50 acres of land of the company for stated compensation of Rs 29.36 crores (the govt. is yet to pay the money) which again points to the figure of ~ 600 crores as market value of land.

Healthcare business

The healthcare business is getting de-merged. The company set up Artemis Hospital in Gurgaon in 2007, spread across 9 acres. The Artemis Hospital in Gurgaon is a 380 bed hospital and can be expanded to 500-550 beds (LINK). Further, the company also runs 50 bed multi-speciality hospital in Dwarka, New Delhi that commenced operations in September 2012.

The incremental CAPEX on expanding the number of beds to 500 will be ~25-30 crores.

The healthcare business of the company is growing rapidly with sales increasing from Rs 216 crores in FY 13 to Rs 400.44 crores in FY 16.

At the same time with improving scale of operations and overheads remaining large fixed, the profitability has improved drastically from Rs 0.17 crores net profit in FY 13 and 6.5 crores in FY 14 to Rs 21.40 crores in FY 16.

With improvement in utilization rate at the two hospitals we expect the profitability to improve further and on a conservative estimate healthcare business can clock net profit of ~23-25 crores in FY 17.

On the basis of earnings, we expect healthcare business to trade at ~ 15-25 times PAT and expect the business to trade at market capitalization of ~360-600 crores.

In unlisted space and in regions like Gurgaon the deals are happening at per bed valuation of Rs 2-3 crores which values healthcare business of PTL in excess of 700 crores, however as we are looking at a listed company we would like to go by earnings based valuations.

Rationale behind this opportunity

The current market capitalization of the company is 785 crores.

On a conservative estimate, we expect Tyre business to get market capitalization of ~350 crores (8 times FY 17 (E) PBT of 43.5 crores) and healthcare business to trade at market cap of ~ 360 crores (15 times FY 17 (E) PAT of 24 crores) i.e. 710 crores on cumulative basis.

Our realistic estimate is that tyre business can trade at ~ 10 times FY 17 (E) PBT of 43.5 crores i.e. market cap of 430 crores and healthcare business at 20 times FY 17 (E) PAT of 24 crores i.e. 480 crores; so cumulative market cap of ~ 910 crores.

Over optimistic estimate would be 500 crore market cap for Tyre business and 600 crores for healthcare business.

So, as we see it the downside seems limited at around 10% while there’s reasonable opportunity of gain for the shareholders through separate listing of the healthcare business.


In de-merger cases the proceedings can get delayed on account of delay in approval by high court (pending in case of PTL) and by stocks exchanges for the listing of resulting company.

In case of deterioration in performance of healthcare business the valuations will get impacted.

Govt. of Kerala has acquired 1.5 acres of land of PTL and hasn’t paid the compensation as yet. Such acquisition in future with inordinate delay in payment of compensation can impact the tyre business of the company.


Disclosure: I do not have any holding in PTL Enterprises.


Best Regards,

Ekansh Mittal

Research Analyst

Ph.: +91-727-5050062, Mob: +91-9818866676



Details of Associates: Not Applicable

Analyst Certification: The Analyst certify (ies) that the views expressed herein accurately reflect his (their) personal view(s) about the subject security (ies) and issuer(s) and that no part of his (their) compensation was, is or will be directly or indirectly related to the specific recommendation(s) or views contained in this research report.

Disclaimer: (here in referred to as Katalyst Wealth) is the domain owned by Ekansh Mittal. Mr. Ekansh Mittal is the sole proprietor of Mittal Consulting and offers independent equity research services to retail clients on subscription basis. SEBI (Research Analyst) Regulations 2014, Registration No. INH100001690

Ekansh Mittal or its associates including its relatives/analyst do not hold beneficial ownership of more than 1% in the company covered by Analyst as of the last day of the month preceding the publication of the research report. Ekansh Mittal or its associates/analyst has not received any compensation from the company/third party covered by Analyst ever. Ekansh Mittal/Mittal Consulting/analyst has not served as an officer, director or employee of company covered by Analyst and has not been engaged in market-making activity of the company covered by Analyst.

We submit that no material disciplinary action has been taken on Ekansh Mittal by any regulatory authority impacting Equity Research Analysis. A graph of daily closing prices of securities is available at

The views expressed are based solely on information available publicly and believed to be true. Investors are advised to independently evaluate the market conditions/risks involved before making any investment decision

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. Ekansh Mittal/Mittal Consulting/Katalyst Wealth is not soliciting any action based upon it. This report is not for public distribution and has been furnished to you solely for your information and should not be reproduced or redistributed to any other person in any form. This document is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. Ekansh Mittal or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. Neither Ekansh Mittal, nor its employees, agents nor representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. Ekansh Mittal/Mittal Consulting or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement.

The recipients of this report should rely on their own investigations. Ekansh Mittal/Mittal Consulting and/or its affiliates and/or employees may have interests/ positions, financial or otherwise in the securities mentioned in this report. Mittal Consulting has incorporated adequate disclosures in this document. This should, however, not be treated as endorsement of the views expressed in the report